Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRIDGEWATER, N.J., MARCH 5, 2026 /PRNEWSWIRE/ --INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO 85 NEW EMPLOYEES.

INSMED REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

COMPANY EXPECTS FULL-YEAR 2026 BRINSUPRI (BRENSOCATIB) REVENUES TO BE AT LEAST $1 BILLION; REITERATES FULL-YEAR 2026 ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) REVENUE GUIDANCE OF$450 MILLIONTO$470 MILLION TOTAL COMPANY REVENUES OF $606.4 MILLION FOR FULL-YEAR 2025 BRINSUPRI TOTAL REVENUES OF $144.6 MILLION FOR FOURTH-QUARTER AND $172.7 MILLION FOR FULL-YEAR 2025 ARIKAYCETOTAL REVENUES OF$119.2 MILLION FOR FOURTH-QUARTER AND $433.8MILLION FOR FULL-YEAR 2025, REPRESENTING 19% ANNUAL GROWTH AND EXCEEDING THE UPPER END OF FULL-YEAR 2025 GUIDANCE TOPLINE DATA READOUTS FROM PHASE 3 ENCORE AND PHASE 2B CEDAR STUDIES REMAIN ON TRACK FDA GRANTS ORPHAN DRUG DESIGNATION TO TREPROSTINIL PALMITIL FOR TREATMENT OF PAH COMPANY ENDS 2025 WITH APPROXIMATELY $1.4 BILLION OF CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES BRIDGEWATER, N.J., FEB. 19, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., FEB. 13, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: 46TH ANNUAL TD COWEN HEALTHCARE CONFERENCE IN BOSTON, ON MONDAY, MARCH 2, 2026, AT 9:50 A.M.

INSMED TO PRESENT AT MARCH 2026 INVESTOR CONFERENCES

BRIDGEWATER, N.J., FEB. 5, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS ONTHURSDAY, FEBRUARY 19, 2026.

INSMED TO HOST FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, FEBRUARY 19, 2026

ABSTRACTS INCLUDE THE PHASE 3 PALM-PAH STUDY DESIGN, A PRESENTATION OF THE PREVIOUSLY DISCLOSED TOPLINE PHASE 2B PAH DATA, A FUNCTIONAL RESPIRATORY IMAGING ANALYSIS FROM THE PHASE 2B STUDY IN PULMONARY ARTERIAL HYPERTENSION (PAH), AND PULMONARY VASODILATION DATA IN RAT MODELS BRIDGEWATER, N.J., JAN. 28, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT FOUR ABSTRACTS ON TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) AT THE PULMONARY VASCULAR RESEARCH INSTITUTE (PVRI) 2026 CONGRESS IN DUBLIN FROM JANUARY 28  FEBRUARY 1, 2026.

INSMED TO PRESENT MULTIPLE ABSTRACTS ON TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) AT PULMONARY VASCULAR RESEARCH INSTITUTE (PVRI) 2026 CONGRESS

NEW YORK, JAN. 22, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF INSMED INCORPORATED ("INSMED" OR THE "COMPANY") (NASDAQ: INSM).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF INSMED INCORPORATED - INSM

NEW YORK, JAN. 15, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF INSMED INCORPORATED ("INSMED" OR THE "COMPANY") (NASDAQ: INSM).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JAN. 13, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF INSMED INCORPORATED (INSMED OR THE COMPANY) (NASDAQ: INSM).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

BRINSUPRI (BRENSOCATIB) UNAUDITED TOTAL REVENUES OF APPROXIMATELY $144.6 MILLION FOR FIRST FULL QUARTER OF LAUNCH; APPROXIMATELY $172.7 MILLION FOR FULL-YEAR 2025 ARIKAYCE(AMIKACIN LIPOSOME INHALATION SUSPENSION) EXCEEDS THE UPPER END OF GUIDANCE RANGE FOR FULL-YEAR 2025 WITH UNAUDITED GLOBAL REVENUES OF APPROXIMATELY$433.8MILLION FULL-YEAR 2026 GLOBAL ARIKAYCE REVENUES EXPECTED TO BE BETWEEN$450 MILLIONAND$470 MILLION TOPLINE DATA FROM PHASE 3 ENCORE STUDY OF ARIKAYCE IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT MAC LUNG DISEASE NOW ANTICIPATED IN MARCH OR APRIL OF 2026  TOPLINE DATA FROM PHASE 2B CEDAR STUDY OF BRENSOCATIB IN PATIENTS WITH HS NOW ANTICIPATED IN THE SECOND QUARTER OF 2026  PHASE 3 PALM-ILD STUDY OF TPIP IN PH-ILD INITIATED IN THE FOURTH QUARTER OF 2025; ADDITIONAL PHASE 3 STUDIES PLANNED FOR PAH, PPF, AND IPF IN 2026 BRIDGEWATER, N.J., JAN. 9, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY PROVIDED AN UPDATE ON THE COMPANY'S COMMERCIAL AND CLINICAL PROGRAMS AND ITS OUTLOOK FOR 2026.

INSMED PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

NEW YORK, JAN. 8, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF INSMED INCORPORATED ("INSMED" OR THE "COMPANY") (NASDAQ: INSM).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

Insmed Incorporated

INSM

Price

Financial Reports

No items found.

Press Releases

Insmed Incorporated

INSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INSM